Dihydroergotamine for migraine: Evidence for multiple modes of action: The single molecule ‘combination’ product—A narrative review

Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study

Long-Term Safety and Tolerability Data of STS101 From the Phase 3 Open-Label ASCEND Study

STS101 Demonstrated Long-Term Clinical Benefit in the Phase 3 Open-Label ASCEND Study

STS101 (Dihydroergotamine Nasal Powder) Shows Long Duration Anti-Migraine Benefit on Baseline Photophobia,Phonophobia, and Nausea: Results From the Phase 3 Double-Blind, Randomized, Placebo-Controlled SUMMIT Study

STS101 (Dihydroergotamine Nasal Powder) Shows Pain Relief in Difficult to Treat Migraine Attacks: Results From the Phase 3 Double-blind, Randomized, Placebo-controlled SUMMIT Study

Subjects View Use of STS101 Favorably: Subject Impression Data From the Phase 3 Open-Label ASCEND Study

A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults

Efficacy of STS101 DHE Nasal Powder for the Acute Treatment of Difficult to Treat Migraines: Results from the Phase 3 Double-Blind, Randomized, Placebo-Controlled SUMMIT Study

Efficacy and Safety of STS101 DHE Nasal Powder for the Acute Treatment of Migraine: Results from the Phase 3 Double-Blind, Randomized, Placebo-Controlled SUMMIT Study